IL199725A - Antibody preparations containing anti-human recombinant epidermal growth factor receptor, a kit containing them, specific bio-specific binding molecules and their uses - Google Patents

Antibody preparations containing anti-human recombinant epidermal growth factor receptor, a kit containing them, specific bio-specific binding molecules and their uses

Info

Publication number
IL199725A
IL199725A IL199725A IL19972509A IL199725A IL 199725 A IL199725 A IL 199725A IL 199725 A IL199725 A IL 199725A IL 19972509 A IL19972509 A IL 19972509A IL 199725 A IL199725 A IL 199725A
Authority
IL
Israel
Prior art keywords
specefic
kit
growth factor
factor receptor
epidermal growth
Prior art date
Application number
IL199725A
Other languages
English (en)
Hebrew (he)
Other versions
IL199725A0 (en
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39495833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL199725(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Symphogen As filed Critical Symphogen As
Publication of IL199725A0 publication Critical patent/IL199725A0/en
Publication of IL199725A publication Critical patent/IL199725A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL199725A 2007-03-01 2009-07-07 Antibody preparations containing anti-human recombinant epidermal growth factor receptor, a kit containing them, specific bio-specific binding molecules and their uses IL199725A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200700317 2007-03-01
US90477307P 2007-03-05 2007-03-05
DKPA200701016 2007-07-10
US92972707P 2007-07-11 2007-07-11
PCT/DK2008/050047 WO2008104183A2 (en) 2007-03-01 2008-02-27 Recombinant anti-epidermal growth factor receptor antibody compositions

Publications (2)

Publication Number Publication Date
IL199725A0 IL199725A0 (en) 2010-04-15
IL199725A true IL199725A (en) 2015-06-30

Family

ID=39495833

Family Applications (2)

Application Number Title Priority Date Filing Date
IL199725A IL199725A (en) 2007-03-01 2009-07-07 Antibody preparations containing anti-human recombinant epidermal growth factor receptor, a kit containing them, specific bio-specific binding molecules and their uses
IL216850A IL216850A (en) 2007-03-01 2011-12-08 Recombinant antibody preparations for epidermal growth factor

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL216850A IL216850A (en) 2007-03-01 2011-12-08 Recombinant antibody preparations for epidermal growth factor

Country Status (18)

Country Link
US (3) US7887805B2 (enExample)
EP (2) EP2725036B1 (enExample)
JP (1) JP5726417B2 (enExample)
KR (2) KR101676622B1 (enExample)
CN (2) CN104151430A (enExample)
AU (1) AU2008221118B2 (enExample)
BR (1) BRPI0808551B1 (enExample)
CA (1) CA2676049C (enExample)
DK (1) DK2132229T3 (enExample)
ES (1) ES2582386T3 (enExample)
HK (1) HK1197252A1 (enExample)
IL (2) IL199725A (enExample)
MX (2) MX2009008909A (enExample)
NZ (2) NZ578943A (enExample)
PL (1) PL2132229T3 (enExample)
RU (1) RU2013119724A (enExample)
TW (1) TWI426083B (enExample)
WO (1) WO2008104183A2 (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2008104183A2 (en) * 2007-03-01 2008-09-04 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
BRPI0808171A2 (pt) * 2007-03-01 2014-08-05 Symphogen As Método para clonagem de anticorpos cognatos
JP2008289483A (ja) * 2007-05-25 2008-12-04 Symphogen As 真核生物系において発現可能な形質転換体のスクリーニング
EP2190878A1 (en) * 2007-09-06 2010-06-02 Genmab A/S Novel methods and antibodies for treating cancer
US20090203038A1 (en) * 2007-12-27 2009-08-13 Abbott Laboratories Negative Mimic Antibody For Use as a Blocking Reagent In BNP Immunoassays
MX2011001930A (es) * 2008-08-29 2011-04-21 Symphogen As Metodo para clonar anticuerpos derivados de aves.
KR101706255B1 (ko) * 2008-08-29 2017-02-14 심포젠 에이/에스 재조합 항-표피 성장 인자 수용체 항체 조성물
US20110224094A1 (en) * 2008-10-06 2011-09-15 Symphogen A/S Method for identifying and selecting drug candidates for combinatorial drug products
FR2942928B1 (fr) 2009-03-03 2011-04-01 Alcatel Lucent Procede et systeme de gestion multicriteres de notifications de presence
FR2945538B1 (fr) * 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
WO2011028961A2 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Anti-botulism antibody coformulations
CA2776508A1 (en) * 2009-10-09 2011-04-14 Symphogen A/S Multiplex quantitation of individual recombinant proteins in a mixture by signature peptides and mass spectrometry
WO2011106707A2 (en) * 2010-02-26 2011-09-01 Human Genome Sciences, Inc. Antibodies that specifically bind to dr3
US8609095B2 (en) 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
US9096660B2 (en) 2010-04-26 2015-08-04 Abraxis Bioscience, Llc SPARC binding antibodies and uses thereof
KR20130060223A (ko) * 2010-05-04 2013-06-07 메리맥 파마슈티컬즈, 인크. 상피세포 성장인자 수용체(ｅｇｆｒ)에 대한 항체 및 이의 용도
WO2011140151A1 (en) * 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
WO2012018260A1 (en) * 2010-08-05 2012-02-09 Universiteit Utrecht Holding B.V. Epidermal growth factor receptor targeted immune therapy
SG189929A1 (en) * 2010-10-29 2013-06-28 Immunogen Inc Novel egfr-binding molecules and immunoconjugates thereof
EP2632947A4 (en) 2010-10-29 2015-03-18 Immunogen Inc NON-ANTAGONIST MOLECULES BINDING TO THE EGF RECEPTOR AND IMMUNOCONJUGATES THEREOF
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
JP6033783B2 (ja) 2010-11-01 2016-11-30 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ Ｐａｎ−ｈｅｒ抗体組成物
DK2663579T3 (en) 2011-01-14 2017-07-31 Univ California THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
SI2668209T1 (sl) 2011-01-24 2021-05-31 Gilead Sciences, Inc. Protitelesa, selektivna za celice, ki predstavljajo egfr pri visoki gostoti
DK2683736T3 (en) 2011-03-09 2018-04-23 Cell Signaling Technology Inc METHODS AND REAGENTS FOR CREATING MONOCLONAL ANTIBODIES
MX2013010379A (es) 2011-03-11 2014-03-27 Merrimack Pharmaceuticals Inc Uso de inhibidores de receptores de la familia egfr en el tratamiento de canceres de mama refractarios a hormonas.
EA201301025A1 (ru) 2011-03-15 2014-01-30 Мерримак Фармасьютикалс, Инк. Преодоление устойчивости к ингибиторам пути erbb
US20120258502A1 (en) * 2011-04-08 2012-10-11 Vinod Pandiripally Method of producing recombinant plasmid dna using substantially solid growth medium
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
RU2014121820A (ru) 2011-11-21 2015-12-27 Иммьюноджен, Инк. Способ лечения опухолей, устойчивых к анти-egfr терапиям, с помощью конъюгата антитела egfr с цитотоксическим средством
EP3663314A1 (en) * 2012-01-09 2020-06-10 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
BR112014027291A2 (pt) 2012-05-02 2017-08-08 Symphogen As composições de anticorpos pan-her humanizados
EP2894472A4 (en) * 2012-09-05 2016-03-30 Jsr Corp METHOD OF SCREENING MATERIAL FOR EPITHELIAL CONSERVATION OF CELLS
EP2912467A4 (en) * 2012-10-26 2016-04-20 Univ Queensland METHOD FOR CLASSIFYING TUMORS AND USE THEREOF
CN102993305B (zh) * 2012-11-16 2015-05-13 上海赛伦生物技术有限公司 人源抗人表皮生长因子受体抗体及其编码基因与应用
US9856319B2 (en) * 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
CN104059148B (zh) * 2013-03-18 2016-09-07 回而生医药科技（北京）有限公司 人源化抗人表皮生长因子受体抗体及其应用
KR20160055253A (ko) * 2013-09-12 2016-05-17 할로자임, 아이엔씨 변형된 항-상피세포 성장인자 수용체 항체 및 이의 사용 방법
EP3096787A4 (en) * 2014-01-22 2018-02-07 The Board of Trustees of the Leland Stanford Junior University Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
GB201402591D0 (en) 2014-02-14 2014-04-02 Memo Therapeutics Ag Method for recovering two or more genes, or gene products, encoding an immunoreceptor
DK3123151T3 (en) * 2014-03-26 2019-03-18 Siemens Healthcare Diagnostics Inc LUMINESCENT OXYGEN CHANNELING IMMUNOASSAY USING THREE ANTIBODIES AND METHODS FOR PRODUCING AND USING THEREOF
MA39599A (fr) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage et administration d'agents thérapeutiques anti-egfr
MA40968A (fr) * 2014-10-31 2017-10-04 Formation Biologics Inc Polythérapie à base d'anticorps anti-egfr
JP6895380B2 (ja) * 2015-02-06 2021-06-30 ナショナル ユニバーシティ オブ シンガポール 治療免疫細胞の有効性を改良するための方法
AU2016252877A1 (en) 2015-04-24 2017-11-09 Merrimack Pharmaceuticals, Inc. Methods of treating patients having mutations in the extracellular domain of epidermal growth factor receptor (EGFR) with a combination of three fully human monoclonal anti-EGFR antibodies
US20190091227A1 (en) 2016-03-15 2019-03-28 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
WO2017205014A1 (en) * 2016-05-26 2017-11-30 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
AU2017292934B9 (en) 2016-07-07 2024-08-29 Bolt Biotherapeutics, Inc. Antibody adjuvant conjugates
KR20190085528A (ko) 2016-11-22 2019-07-18 싱가포르국립대학교 T 세포 악성종양의 면역요법을 위한 키메라 항원 수용체 및 cd7 발현의 차단
KR102702552B1 (ko) * 2016-12-23 2024-09-03 비스테라, 인크. 결합 폴리펩타이드 및 이의 제조 방법
US11124575B2 (en) * 2017-02-22 2021-09-21 University Of Saskatchewan EGFR-binding agents and uses thereof
WO2018166119A1 (zh) * 2017-03-14 2018-09-20 北京伟峰益民科技有限公司 一种多肽或其衍生物及其在制备治疗肿瘤的药物中的应用
JP2020530291A (ja) 2017-08-10 2020-10-22 ナショナル ユニバーシティ オブ シンガポール Ｔ細胞受容体欠損キメラ抗原受容体ｔ細胞およびその使用方法
EP3695013A1 (en) 2017-08-30 2020-08-19 Symphogen A/S Compositions and methods for treating cancer with anti-egfr antibodies
CN109912716B (zh) * 2017-12-13 2022-08-23 凯惠科技发展(上海)有限公司 一种egfr抗体及其制备方法和应用
EP3743109A4 (en) * 2018-01-25 2021-11-10 Cullinan Mica Corp. MICA / B ANTIBODIES AND METHOD OF USE
SG11202010996QA (en) 2018-05-23 2020-12-30 Nat Univ Singapore Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
US11274035B2 (en) 2019-04-24 2022-03-15 X-Celeprint Limited Overhanging device structures and related methods of manufacture
US12162747B2 (en) 2018-12-03 2024-12-10 X-Celeprint Limited Enclosed cavity structures
US10456776B1 (en) 2019-02-21 2019-10-29 King Saud University Method of fabricating a photocatalyst for water splitting
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
CN111018990A (zh) * 2020-02-10 2020-04-17 张喜田 一种新型的重组抗表皮生长因子受体单克隆抗体及其应用
KR20240067131A (ko) 2021-10-04 2024-05-16 르 라보레또레 쎄르비에르 Nkg2a를 표적화하는 암 요법
AR127893A1 (es) 2021-12-10 2024-03-06 Servier Lab Terapia del cáncer dirigida a egfr

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5459061A (en) * 1990-01-26 1995-10-17 W. Alton Jones Cell Science Center, Inc. Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
KR100240308B1 (ko) 1991-03-06 2000-01-15 플레믹 크리스티안 인간화된단클론성항체및혼성단클론성항체
AU687346B2 (en) 1992-06-30 1998-02-26 Oncologix, Inc. A combination of anti-erbB-2 monoclonal antibodies and method of using
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP1268803A2 (en) 2000-03-23 2003-01-02 Greenville Hospital System Bi-functional cancer treatment agents
ES2259030T3 (es) * 2000-05-19 2006-09-16 Scancell Limited Anticuerpos humanizados frente al receptor del factor de crecimiento epidermico.
US6849259B2 (en) * 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
EP1361893B1 (en) * 2001-02-19 2012-10-24 Merck Patent GmbH Modified anti-egfr antibodies with reduced immunogenicity
PT2163256E (pt) 2001-05-11 2015-11-20 Ludwig Inst For Cancer Res Ltd Proteínas de ligação específica e suas utilizações
IL159225A0 (en) * 2001-06-13 2004-06-01 Genmab As Human monoclonal antibodies to epidermal growth factor receptor (egfr)
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
AU2002326531A1 (en) * 2001-08-03 2003-02-17 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbb family members and methods of use thereof
WO2003074705A1 (fr) 2002-03-01 2003-09-12 Japan Envirochemicals, Ltd. Proteines capables de se fixer sur des hormones environnementales et procede permettant de les produire
WO2003097086A2 (en) 2002-05-15 2003-11-27 Technische Universität München Egf receptor antagonists in the treatment of gastric cancer
EP1575491A4 (en) 2002-05-20 2006-09-27 Abgenix Inc TREATMENT OF RENAL CARCINOMA USING ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR
NZ537660A (en) 2002-07-15 2008-12-24 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies
ES2368733T3 (es) 2002-07-18 2011-11-21 Merus B.V. Producción recombinante de mezclas de anticuerpos.
US7226592B2 (en) 2002-10-10 2007-06-05 Merck Patent Gmbh Bispecific anti-Erb-B antibodies and their use in tumor therapy
ATE338816T1 (de) 2003-01-07 2006-09-15 Symphogen As Verfahren zur herstellung rekombinanterpolyklonaler proteine
US20060275766A1 (en) * 2003-01-07 2006-12-07 Haurum John S Method for manufacturing recombinant polyclonal proteins
CA2450289A1 (en) 2003-03-20 2005-05-19 Imclone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
AT500651B9 (de) 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
WO2005071075A1 (ja) 2004-01-23 2005-08-04 Green Peptide Co., Ltd. 上皮細胞増殖因子受容体（egfr）由来ペプチド
US20110142822A1 (en) 2004-06-14 2011-06-16 Kussie Paul H Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof
WO2006007853A2 (en) 2004-07-20 2006-01-26 Symphogen A/S A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
US8198415B2 (en) * 2004-07-20 2012-06-12 Symphogen A/S Anti-rhesus D recombinant polyclonal antibody
TWI441646B (zh) 2005-01-21 2014-06-21 Genentech Inc 帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途
US20070009972A1 (en) * 2005-02-16 2007-01-11 Ginger Chao Epidermal growth factor receptor polypeptides and antibodies
MY152164A (en) 2005-02-23 2014-08-15 Genentech Inc Extending time to disease progression or survival in cancer patients
US7981605B2 (en) 2005-02-24 2011-07-19 Amgen Inc. Epidermal growth factor receptor mutations
US20060216288A1 (en) 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
WO2006110478A2 (en) 2005-04-11 2006-10-19 Novartis Ag Mutations and polymorphisms of epidermal growth factor receptor
BRPI0610440A2 (pt) 2005-04-14 2010-06-22 Merck Patent Gmbh terapia com anticorpo anti-egfr baseada em um maior número de cópias do gene egfr em tecidos de tumores
CN101277716A (zh) 2005-04-27 2008-10-01 回而生医药科技有限公司 治疗癌症的抗体
HRP20151102T1 (xx) * 2005-07-01 2015-11-20 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1)
CN101627054A (zh) * 2005-07-11 2010-01-13 马克罗基因公司 用人源化抗cd16a抗体治疗自身免疫疾病的方法
AU2006322445B2 (en) 2005-12-05 2011-05-12 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
US7498142B2 (en) * 2006-01-31 2009-03-03 Yeda Research And Development Co., Ltd. Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
AU2007222798A1 (en) 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
WO2008104183A2 (en) 2007-03-01 2008-09-04 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
BRPI0808171A2 (pt) * 2007-03-01 2014-08-05 Symphogen As Método para clonagem de anticorpos cognatos
JP2008289483A (ja) * 2007-05-25 2008-12-04 Symphogen As 真核生物系において発現可能な形質転換体のスクリーニング
KR101706255B1 (ko) 2008-08-29 2017-02-14 심포젠 에이/에스 재조합 항-표피 성장 인자 수용체 항체 조성물
US9155802B2 (en) * 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition

Also Published As

Publication number Publication date
ES2582386T3 (es) 2016-09-12
MX338151B (es) 2016-04-05
EP2725036B1 (en) 2017-10-25
NZ597466A (en) 2013-08-30
BRPI0808551A2 (pt) 2014-08-19
JP2010535012A (ja) 2010-11-18
EP2725036A1 (en) 2014-04-30
US8414896B2 (en) 2013-04-09
AU2008221118A1 (en) 2008-09-04
NZ578943A (en) 2012-09-28
AU2008221118B2 (en) 2013-10-03
WO2008104183A2 (en) 2008-09-04
TWI426083B (zh) 2014-02-11
IL216850A0 (en) 2012-01-31
DK2132229T3 (en) 2016-06-20
CN104151430A (zh) 2014-11-19
KR20100014722A (ko) 2010-02-10
CN101675075B (zh) 2014-06-18
BRPI0808551B1 (pt) 2022-04-05
WO2008104183A3 (en) 2008-11-13
IL216850A (en) 2014-06-30
US20110135636A1 (en) 2011-06-09
US7887805B2 (en) 2011-02-15
TW200902552A (en) 2009-01-16
KR101805140B1 (ko) 2017-12-05
CA2676049A1 (en) 2008-09-04
EP2132229A2 (en) 2009-12-16
HK1134826A1 (zh) 2010-06-11
RU2013119724A (ru) 2014-11-10
CA2676049C (en) 2018-04-10
KR101676622B1 (ko) 2016-11-17
HK1197252A1 (en) 2015-01-09
PL2132229T3 (pl) 2016-12-30
KR20160132132A (ko) 2016-11-16
CN101675075A (zh) 2010-03-17
EP2132229B1 (en) 2016-05-11
US20090004192A1 (en) 2009-01-01
IL199725A0 (en) 2010-04-15
JP5726417B2 (ja) 2015-06-03
MX2009008909A (es) 2009-08-28
US20110129855A1 (en) 2011-06-02

Similar Documents

Publication Publication Date Title
IL199725A (en) Antibody preparations containing anti-human recombinant epidermal growth factor receptor, a kit containing them, specific bio-specific binding molecules and their uses
IL265854A (en) Antigen binding proteins capable of binding thymic subset of lymphopoietin
IL205569A0 (en) Wise binding antibodies and epitopes
IL195037A0 (en) Binding proteins that bind hepatocyte growth factor
IL206188A0 (en) Antigen binding proteins
IL245666A0 (en) Interleukin-13 binding proteins
IL204757A0 (en) Heparin - binding epidermal growth factor - like growth factor antigen binding proteins
IL234081B (en) Antibody binds cd3–epsilon in different species
LT3165539T (lt) Il-17 receptoriaus a antigenus surišantys baltymai
IL201340A (en) Antidote 3dc - epsilon in various species
ZA201003496B (en) Monoclonal antibody capable of binding to anexelekto,and use thereof
IL232009A (en) Protein isolate heterodimer alpha 4 in cell 7 specific antigen-binding and various aspects thereof
ZA201303003B (en) Single-chain multivalent binding proteins with effector function
IL195038A0 (en) Hepatocyte growth factor binding proteins
IL202259A0 (en) Antigen binding proteins that bind par-2
PL1899377T3 (pl) Humanizowane przeciwciała specyficzne dla nogo-a i ich zastosowania farmaceutyczne
HK1147764A (en) Wise binding antibodies and epitopes
HK1147763A (en) Antigen binding proteins
IL182717A0 (en) Antibodies to interferon - ??/?? binding protein
AU2013200711B2 (en) Interleukin -13 binding proteins
AU2007901644A0 (en) Novel Telomerase Peptide and Antibody
ZA201000706B (en) Antigen binding proteins that bind par-2
HK1145505A (en) Anti-chikungunya monoclonal antibodies and uses thereof
AU2007900058A0 (en) Recombinant Antibodies

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed